NCT06533384View on ClinicalTrials.gov

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

PHASE3RecruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Triple-negative Breast Cancer
Interventions
DRUG

As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.

As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.

DRUG

9 cycles of Camrelizumab as adjuvant therapy.

9 cycles of Camrelizumab as adjuvant therapy.

Trial Locations (1)

510080

RECRUITING

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER